Alkermes plc - Wikipedia Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders The company was founded in 1987 by Michael Wall [3]
Alkermes plc Announces Increased Offer to Acquire Avadel . . . Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended
With $2. 37B offer, Alkermes sweetens deal to acquire Avadel Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal
Alkermes Agrees to Higher Takeover Price for Avadel Alkermes struck a revised deal to buy fellow biopharmaceutical company Avadel Pharmaceuticals for up to $2 37 billion, fending off a spoiler bid from Danish drugmaker H Lundbeck Alkermes it will
About Alkermes | Alkermes At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders
Home - The Narcolepsy Project For the latest information on narcolepsy and idiopathic hypersomnia research initiatives, enrolling clinical trials and approved medications